Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
WD repeat-containing protein 82 (WDR82) is a nuclear scaffold protein with seven WD40 domains that acts primarily as a regulatory component of the SET1/COMPASS histone H3K4 methyltransferase complex, facilitating the recruitment of SETD1A or SETD1B to the phosphorylated C-terminal domain of RNA polymerase II at transcriptional start sites, enabling proper gene activation through H3K4 trimethylation[2][3][5]. WDR82 is also a component of the PNUTS-PP1 phosphatase complex, contributing to chromatin structure regulation and cell cycle progression[3][5]. It is essential for normal embryonic development, pluripotency maintenance, transcriptional regulation, and metabolic pathway modulation during somatic cell reprogramming[1][2][3]. Loss of WDR82 disrupts normal histone methylation and impairs proliferation and differentiation, and rare genetic defects in WDR82 are associated with specific neurodevelopmental and skeletal disorders[3][5]. There is no evidence to date that WDR82 is a direct target for therapeutic small molecules or biologic drugs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on WD repeat-containing protein 82 (WDR82).